Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
resection across 10 Chinese hepatobiliary centers and remained recurrence-free at 2 years after hepatectomy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
By integrating tumor characteristics and host factors, this prediction tool identified high-risk patients who may benefit from intensified recurrence surveillance, potentially improving long-term survival through earlier detection of POLAR. The model represents an important step toward personalized surveillance strategies among patients undergoing HCC resection.
[BACKGROUND] Postoperative late recurrence (POLAR) after 2 years from the date of surgical resection of hepatocellular carcinoma (HCC) represents a unique surveillance and management challenge.
- p-value p = 0.04
- p-value p = 0.008
APA
Xu XF, Wu H, et al. (2025). Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.. Annals of surgical oncology, 32(13), 9573-9583. https://doi.org/10.1245/s10434-025-18213-9
MLA
Xu XF, et al.. "Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.." Annals of surgical oncology, vol. 32, no. 13, 2025, pp. 9573-9583.
PMID
40928575 ↗
Abstract 한글 요약
[BACKGROUND] Postoperative late recurrence (POLAR) after 2 years from the date of surgical resection of hepatocellular carcinoma (HCC) represents a unique surveillance and management challenge. Despite identified risk factors, individualized prediction tools to guide personalized surveillance strategies for recurrence remain scarce. The current study sought to develop a predictive model for late recurrence among patients undergoing HCC resection.
[METHODS] This multicenter study analyzed HCC patients who underwent resection across 10 Chinese hepatobiliary centers and remained recurrence-free at 2 years after hepatectomy. Patients were randomly assigned to development and validation cohorts (2:1 ratio). Independent predictors identified through multivariate Cox regression analysis were integrated into a nomogram and web-based calculator.
[RESULTS] Among 849 recurrence-free patients at 2 years after hepatectomy for HCC, seven independent predictors of POLAR were identified: male (hazard ratio [HR] 1.37, p = 0.04), cirrhosis (HR 1.42, p = 0.008), multiple tumors (HR 1.56, p = 0.006), satellite nodules (HR 1.59, p = 0.004), large tumor size (HR 1.49, p = 0.009), macrovascular invasion (HR 4.63, p < 0.001), and microvascular invasion (HR 1.69, p = 0.001). The POLAR-HCC nomogram-based calculator demonstrated robust performance in both the development (area under the curve [AUC] 0.660) and validation (AUC 0.626) cohorts. Using the optimal cut-off value of 1.93, patients were accurately stratified into high- and low-risk groups with different risks of POLAR (p < 0.001).
[CONCLUSIONS] The POLAR-HCC online calculator enables risk stratification for POLAR after HCC resection. By integrating tumor characteristics and host factors, this prediction tool identified high-risk patients who may benefit from intensified recurrence surveillance, potentially improving long-term survival through earlier detection of POLAR. The model represents an important step toward personalized surveillance strategies among patients undergoing HCC resection.
[METHODS] This multicenter study analyzed HCC patients who underwent resection across 10 Chinese hepatobiliary centers and remained recurrence-free at 2 years after hepatectomy. Patients were randomly assigned to development and validation cohorts (2:1 ratio). Independent predictors identified through multivariate Cox regression analysis were integrated into a nomogram and web-based calculator.
[RESULTS] Among 849 recurrence-free patients at 2 years after hepatectomy for HCC, seven independent predictors of POLAR were identified: male (hazard ratio [HR] 1.37, p = 0.04), cirrhosis (HR 1.42, p = 0.008), multiple tumors (HR 1.56, p = 0.006), satellite nodules (HR 1.59, p = 0.004), large tumor size (HR 1.49, p = 0.009), macrovascular invasion (HR 4.63, p < 0.001), and microvascular invasion (HR 1.69, p = 0.001). The POLAR-HCC nomogram-based calculator demonstrated robust performance in both the development (area under the curve [AUC] 0.660) and validation (AUC 0.626) cohorts. Using the optimal cut-off value of 1.93, patients were accurately stratified into high- and low-risk groups with different risks of POLAR (p < 0.001).
[CONCLUSIONS] The POLAR-HCC online calculator enables risk stratification for POLAR after HCC resection. By integrating tumor characteristics and host factors, this prediction tool identified high-risk patients who may benefit from intensified recurrence surveillance, potentially improving long-term survival through earlier detection of POLAR. The model represents an important step toward personalized surveillance strategies among patients undergoing HCC resection.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (4)
- ASO Visual Abstract: Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence after Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.
- Reply to Letter to the Editor: Predicting Late Tumor Recurrence in Surgical Hepatocellular Carcinoma: What have We Missed?
- ASO Author Reflections: Reconsidering Late Recurrence After Hepatectomy for Hepatocellular Carcinoma: Insights from Predictive Modeling.
- Host-microbiota interactions in genitourinary cancer immunotherapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.